drugset / Trial / NCT00002423

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423

Phase 2 Completed 100 enrolled Glaxo Wellcome
Treatment

Summary

This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.

Timeline

Start
1999-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg
Subject Nelfinavir Other / unclassified 1250 mg
Background Abacavir Other / unclassified 300 mg
Background Amprenavir Other / unclassified 1200 mg
Background Lamivudine Other / unclassified 150 mg